AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32598397 — intervention group
Group type: COMPARATOR
Intervention: European adolescents
Number of subjects: 1215
Study 36136861 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium
Number of subjects: 81
Study 36136861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 33166622 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes education plus food vouchers
Number of subjects: 300
Study 33166622 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes education plus stock boxes
Number of subjects: 300
Study 33166622 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes education plus combined food vouchers and stock boxes
Number of subjects: 300
Study 33166622 — intervention group
Group type: COMPARATOR
Intervention: Diabetes education alone
Number of subjects: 300
Study 34397606 — intervention group
Group type: EXPERIMENTAL
Intervention: Music listening on headphones
Number of subjects: 69
Study 34397606 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 69
Study 34397606 — intervention group
Group type: EXPERIMENTAL
Intervention: Music listening
Number of subjects: 69
Study 32331090 — intervention group
Group type: EXPERIMENTAL
Intervention: OLZ/SAM
Number of subjects: 561
Study 32331090 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 561
Study 36206208 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based occupational therapy intervention (COT-MHABI) over one year, 16 sessions on average.
Number of subjects: 0
Study 36206208 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline, 6 months, and 12 months assessments.
Number of subjects: 0
Study 32946836 — intervention group
Group type: EXPERIMENTAL
Intervention: C difficile vaccine candidate (0.5 mL administered intramuscularly on days 0, 7, and 30)
Number of subjects: 9302
Study 32946836 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaccine (0.5 mL administered intramuscularly on days 0, 7, and 30)
Number of subjects: 9302
Study 32946836 — intervention group
Group type: EXPERIMENTAL
Intervention: C difficile vaccine candidate
Number of subjects: 9302
Study 32946836 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaccine
Number of subjects: 9302
Study 33970752 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of fast-release melatonin
Number of subjects: 8
Study 33970752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 34999239 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ivermectin 1200 μg/kg for 5 days (arm C)
Number of subjects: 93
Study 34999239 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ivermectin 600 μg/kg plus placebo for 5 days (arm B)
Number of subjects: 93
Study 34999239 — intervention group
Group type: COMPARATOR
Intervention: Placebo (arm A)
Number of subjects: 93
Study 32691207 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (surgery at 2 cm proximally to the pylorus)
Number of subjects: 150
Study 32691207 — intervention group
Group type: COMPARATOR
Intervention: Group B (surgery at 6 cm proximally to the pylorus)
Number of subjects: 150
Study 32691207 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 150
Study 32691207 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 150
Study 32000208 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA) intervention conducted in a hospital setting over 5 months.
Number of subjects: 71
Study 36075243 — intervention group
Group type: EXPERIMENTAL
Intervention: Brensocatib 25 mg once daily for 28 days
Number of subjects: 406
Study 36075243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study 36075243 — intervention group
Group type: EXPERIMENTAL
Intervention: Brensocatib
Number of subjects: 406
Study 32056346 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 7213
Study 32056346 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 7213
Study 35152573 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongdu Tiaoshen acupuncture combined with carotid endarterectomy (CEA)
Number of subjects: 60
Study 35152573 — intervention group
Group type: COMPARATOR
Intervention: Simple carotid endarterectomy (CEA) with conventional treatment (aspirin and clopidogrel)
Number of subjects: 60
Study 36038929 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted, theory-informed interventions (clinical leads, stakeholder meetings, train-the-trainer workshop, targeted educational package, audit/feedback)
Number of subjects: 1800
Study 36038929 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention hospitals
Number of subjects: 1800
Study 36038929 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals
Number of subjects: 1800
Study 34555929 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care coaching
Number of subjects: 350
Study 34555929 — intervention group
Group type: COMPARATOR
Intervention: Structured usual care
Number of subjects: 350
Study 36308070 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNβ‐1a
Number of subjects: 36
Study 36308070 — intervention group
Group type: EXPERIMENTAL
Intervention: pegIFNβ‐1a
Number of subjects: 36
Study 33646179 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancers (melanoma, breast, prostate, endometrial, keratinocyte)
Number of subjects: 15
Study 33646179 — intervention group
Group type: COMPARATOR
Intervention: Parkinson's disease (PD)
Number of subjects: 15
Study 32835895 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Outcomes By You application
Number of subjects: 15
Study 35578536 — intervention group
Group type: EXPERIMENTAL
Intervention: HBOT plus venous intervention
Number of subjects: 33
Study 35578536 — intervention group
Group type: COMPARATOR
Intervention: Venous intervention alone
Number of subjects: 33
Study 34456586 — intervention group
Group type: EXPERIMENTAL
Intervention: TPVB with 0.5% ropivacaine
Number of subjects: 68
Study 34456586 — intervention group
Group type: COMPARATOR
Intervention: Control with 0.9% saline
Number of subjects: 68
Study 33059356 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD 25 µg
Number of subjects: 16
Study 33059356 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD 50 µg
Number of subjects: 16
Study 33059356 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD 100 µg
Number of subjects: 16
Study 33059356 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD 200 µg
Number of subjects: 16
Study 33059356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 33059356 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg + LSD 200 µg
Number of subjects: 16
Study 33059356 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD (25-200 µg)
Number of subjects: 16
Study 33188930 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, specific dosage and duration not available
Number of subjects: 0
Study 33188930 — intervention group
Group type: COMPARATOR
Intervention: Propensity score methods, including g-computation and doubly robust estimators, specific details not available
Number of subjects: 0
Study 34824100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (hs-cTnT <5 ng/L at presentation)
Number of subjects: 10315
Study 34824100 — intervention group
Group type: COMPARATOR
Intervention: Standard care group (hs-cTnT <99th centile at presentation)
Number of subjects: 10315
Study 34267331 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest (RF) model
Number of subjects: 778
Study 34267331 — intervention group
Group type: COMPARATOR
Intervention: PSA
Number of subjects: 778
Study 34267331 — intervention group
Group type: COMPARATOR
Intervention: PSA density
Number of subjects: 778
Study 34267331 — intervention group
Group type: COMPARATOR
Intervention: ERSPC risk calculator (ERSPC-RC)
Number of subjects: 778
Study 34267331 — intervention group
Group type: COMPARATOR
Intervention: Various ML techniques (XGBoost, LightGBM, Catboost, Support vector machine (SVM), Logistic regression (LR))
Number of subjects: 778
Study 33338271 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial literacy intervention (Moving Ahead)
Number of subjects: 449
Study 33338271 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 449
Study 35537533 — intervention group
Group type: EXPERIMENTAL
Intervention: Brolucizumab 6 mg every 4 weeks
Number of subjects: 0
Study 35537533 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept 2 mg every 4 weeks
Number of subjects: 0
Study 35537533 — intervention group
Group type: EXPERIMENTAL
Intervention: Brolucizumab 6 mg
Number of subjects: 0
Study 35537533 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept 2 mg
Number of subjects: 0
Study 32317794 — intervention group
Group type: EXPERIMENTAL
Intervention: Optometrists
Number of subjects: 129
Study 32317794 — intervention group
Group type: COMPARATOR
Intervention: Ophthalmologists
Number of subjects: 129
Study 32514076 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-c (low density lipoprotein cholesterol)
Number of subjects: 0
Study 32514076 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL-c (high density lipoprotein cholesterol)
Number of subjects: 0
Study 32514076 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides (TG)
Number of subjects: 0
Study 35986699 — intervention group
Group type: EXPERIMENTAL
Intervention: brepocitinib 1% QD
Number of subjects: 292
Study 35986699 — intervention group
Group type: EXPERIMENTAL
Intervention: brepocitinib 1% BID
Number of subjects: 292
Study 35986699 — intervention group
Group type: COMPARATOR
Intervention: vehicle QD
Number of subjects: 292
Study 35986699 — intervention group
Group type: COMPARATOR
Intervention: vehicle BID
Number of subjects: 292
Study 32404117 — intervention group
Group type: EXPERIMENTAL
Intervention: Group P (FiO2 = 0.6, inhaling PGE1 0.1 μg/kg)
Number of subjects: 90
Study 32404117 — intervention group
Group type: EXPERIMENTAL
Intervention: Group P and Group L
Number of subjects: 90
Study 32404117 — intervention group
Group type: COMPARATOR
Intervention: Group C (FiO2 = 1.0)
Number of subjects: 90
Study 32404117 — intervention group
Group type: EXPERIMENTAL
Intervention: Group P, Group L, and Group C
Number of subjects: 90
Study 35475761 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Chatbot (free-choice group)
Number of subjects: 251
Study 35475761 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialogical-Self Chatbot (free-choice group)
Number of subjects: 251
Study 35475761 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert Chatbot (younger participants < 40 years)
Number of subjects: 251
Study 35475761 — intervention group
Group type: EXPERIMENTAL
Intervention: Institution Chatbot (younger participants < 40 years)
Number of subjects: 251
Study 35475761 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Chatbot (older participants ≥ 40 years)
Number of subjects: 251
Study 35475761 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialogical-Self Chatbot (older participants ≥ 40 years)
Number of subjects: 251
Study 35475761 — intervention group
Group type: COMPARATOR
Intervention: No-choice group (general)
Number of subjects: 251
Study 34520489 — intervention group
Group type: COMPARATOR
Intervention: Class 1 (low PIU risk)
Number of subjects: 1066
Study 34520489 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 2 (high PIU risk)
Number of subjects: 1066
Study 36282895 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression garment (n = 16)
Number of subjects: 32
Study 36282895 — intervention group
Group type: COMPARATOR
Intervention: No compression garment (n = 16)
Number of subjects: 32
Study 33331622 — intervention group
Group type: EXPERIMENTAL
Intervention: Early in-bed cycling plus routine physiotherapy
Number of subjects: 66
Study 33331622 — intervention group
Group type: COMPARATOR
Intervention: Early routine physiotherapy alone
Number of subjects: 66
Study 33331622 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 66
Study 35086420 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 12
Study 34494595 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with adrenaline
Number of subjects: 60
Study 34494595 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 60
Study 32465073 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVL) and low-dose tacrolimus (LD-TAC)
Number of subjects: 210
Study 32465073 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (TAC) and mycophenolate mofetil (MMF)
Number of subjects: 210
Study 35659597 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy in 5 fractions
Number of subjects: 50
Study 33706522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol nanoparticles (group 1, n=5)
Number of subjects: 13
Study 33706522 — intervention group
Group type: COMPARATOR
Intervention: Ferumoxytol nanoparticles (group 2, n=8)
Number of subjects: 13
Study 32951744 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal massage for 15 minutes daily (Group A)
Number of subjects: 143
Study 32951744 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG 20g daily (Group B)
Number of subjects: 143
Study 32951744 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG 20g plus abdominal massage for 15 minutes daily (Group C)
Number of subjects: 143
Study 35628840 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emptive analgesic acetaminophen (15 mg/kg)
Number of subjects: 51
Study 35628840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 32555027 — intervention group
Group type: EXPERIMENTAL
Intervention: Land Walking (LW)
Number of subjects: 51
Study 32555027 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 51
Study 34784897 — intervention group
Group type: EXPERIMENTAL
Intervention: PREPARED Trial intervention
Number of subjects: 400
Study 34784897 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 400
Study 32235038 — intervention group
Group type: EXPERIMENTAL
Intervention: BIC/F/TAF
Number of subjects: 943
Study 32235038 — intervention group
Group type: COMPARATOR
Intervention: DTG-based regimens
Number of subjects: 943
Study 36206649 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compassion (SC) meditation intervention (3 weeks)
Number of subjects: 71
Study 36206649 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 71
Study 35700207 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundled devices (BDs)
Number of subjects: 989
Study 35700207 — intervention group
Group type: COMPARATOR
Intervention: Standard devices (SDs)
Number of subjects: 989
Study 33831899 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (0.5 mg/kg bolus over 10 min followed by continuous infusion of 100 μg/kg/min)
Number of subjects: 70
Study 33831899 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 70
Study 33831899 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 70
Study 34980867 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid
Number of subjects: 0
Study 34980867 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid and ezetimibe combination
Number of subjects: 0
Study 34980867 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Number of subjects: 0
Study 34980867 — intervention group
Group type: COMPARATOR
Intervention: Statins
Number of subjects: 0
Study 33176703 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based multicomponent high intensity exercise program led by a physiotherapist twice a week for 4 months.
Number of subjects: 89
Study 33176703 — intervention group
Group type: COMPARATOR
Intervention: Control group (home-based exercise program with encouragement to exercise according to WHO recommendations).
Number of subjects: 89
Study 36564950 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined SST and LLLT
Number of subjects: 42
Study 36564950 — intervention group
Group type: COMPARATOR
Intervention: LLLT
Number of subjects: 42
Study 36564950 — intervention group
Group type: COMPARATOR
Intervention: SST
Number of subjects: 42
Study 34480880 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily for 35 ± 4 days
Number of subjects: 0
Study 34480880 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study 36273203 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-VTE risk probability calculated from a validated VTE risk-prediction model with daily updates; additional review by hematologists for patients with elevated risk (predicted probability of HA-VTE ≥ 0.025) including recommendations for pharmacologic prophylaxis if appropriate.
Number of subjects: 15000
Study 32270182 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 1635
Study 32270182 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 1635
Study 35860187 — intervention group
Group type: EXPERIMENTAL
Intervention: ICGA + ICAC + perioperative nursing
Number of subjects: 86
Study 35860187 — intervention group
Group type: COMPARATOR
Intervention: ICAC + conventional nursing
Number of subjects: 86
Study 33172456 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser pre-treatment (energy 50-300 mJ, frequency 5-30 Hz)
Number of subjects: 4
Study 33172456 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 4
Study 33172456 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional acid etching treatment
Number of subjects: 4
Study 33174761 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare-metal stent plus 1 mg of colchicine for 3 months
Number of subjects: 0
Study 33174761 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stent alone
Number of subjects: 0
Study 35183498 — intervention group
Group type: EXPERIMENTAL
Intervention: Isonicotinic acid hydrazide (INH) 900 mg vaginally
Number of subjects: 0
Study 35183498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33821679 — intervention group
Group type: EXPERIMENTAL
Intervention: Tu’Washindi na PrEP intervention
Number of subjects: 0
Study 32951737 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching comedy movies during dialysis (experimental group)
Number of subjects: 61
Study 32951737 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 61
Study 35880807 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diabetes therapy
Number of subjects: 1094
Study 35880807 — intervention group
Group type: COMPARATOR
Intervention: Conventional diabetes therapy
Number of subjects: 1094
Study 35880807 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 1094
Study 34076966 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-11 (60 mg/m2 on days 1 and 8) every three weeks
Number of subjects: 14
Study 34076966 — intervention group
Group type: EXPERIMENTAL
Intervention: AMR (35 mg/m2 on days 1–3) every three weeks
Number of subjects: 14
Study 34076966 — intervention group
Group type: COMPARATOR
Intervention: CPT-11
Number of subjects: 14
Study 34076966 — intervention group
Group type: COMPARATOR
Intervention: AMR
Number of subjects: 14
Study 35867857 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (n = 39) received spinal anesthesia with intrathecal morphine, periarticular local anesthesia infiltration, intravenous dexamethasone, single injection adductor canal block, plus five additional interventions: local anesthetic infiltration between the popliteal artery and capsule of the posterior knee, intraoperative intravenous dexmedetomidine and ketamine, one additional intravenous dexamethasone bolus, and two additional adductor canal block injections.
Number of subjects: 78
Study 35867857 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 39) received spinal anesthesia with intrathecal morphine, periarticular local anesthesia infiltration, intravenous dexamethasone, and a single injection adductor canal block.
Number of subjects: 78
Study 35867857 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (n = 39)
Number of subjects: 78
Study 35867857 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 39)
Number of subjects: 78
Study 34198135 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2.0 mA)
Number of subjects: 44
Study 34198135 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (0.3 mA)
Number of subjects: 44
Study 35846796 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 120
Study 35846796 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 120
Study 34914726 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine
Number of subjects: 554
Study 34914726 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplement (Lactobacillus helveticus R0052 and Lactobacillus rhamnosus R0011)
Number of subjects: 554
Study 34914726 — intervention group
Group type: COMPARATOR
Intervention: Influenza vaccine
Number of subjects: 554
Study 34914726 — intervention group
Group type: COMPARATOR
Intervention: Probiotic group
Number of subjects: 554
Study 33008780 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching a relaxing video during cystoscopy
Number of subjects: 60
Study 33008780 — intervention group
Group type: COMPARATOR
Intervention: Control group (no video)
Number of subjects: 60
Study 35338847 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g/day of n‐3 PUFA
Number of subjects: 193
Study 35338847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 32379227 — intervention group
Group type: EXPERIMENTAL
Intervention: Taylor Spatial Frame (TSF)
Number of subjects: 63
Study 32379227 — intervention group
Group type: COMPARATOR
Intervention: Reamed intramedullary nailing (IMN)
Number of subjects: 63
Study 34142339 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SBP increase of 10 mm Hg
Number of subjects: 139
Study 34142339 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-recanalization SBP increase of 10 mm Hg
Number of subjects: 139
Study 34142339 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline MAP increase of 10 mm Hg
Number of subjects: 139
Study 34142339 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-recanalization MAP increase of 10 mm Hg
Number of subjects: 139
Study 34142339 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP of 163 mm Hg and MAP of 117 mm Hg during pre-recanalization phase
Number of subjects: 139